MedTrace Logo

Atrial Fibrillation Prediction Trial.

NCT02307032 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2016-01-28

No results posted yet for this study

Summary

Atrial Fibrillation (AF) is a common arrhythmia with a prevalence of 1.5-2%. This prevalence increases significantly after 80 years of age. After the appearance of first episode(s) some of the patients will present frequent arrhythmia recurrences moving from the paroxysmal status to the persistent and the permanent status of the continuous spectrum of the natural time course of AF. In contrast some other will not present further relapses. To study and predict the dynamic evolution of AF is clinically important, furthermore, the detection of different sub populations risk for AF relapses will determine and different therapeutic approaches.

Conditions

Sponsors & Collaborators

  • University of Athens

    lead OTHER

Principal Investigators

  • Petros Arsenos, MD, PhD · First Department of Cardiology, Medical School, National & Kapodistrian University of Athens, Greece

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2019-01-31
Completion
2020-12-31

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02307032 on ClinicalTrials.gov